Corneal endothelium after phakic iris-claw intraocular lens implantation vs corneal refractive surgery or no surgery: a paired eye comparison

Session Details

Session Title: Phakic IOLs I

Session Date/Time: Monday 07/09/2015 | 14:30-16:30

Paper Time: 14:54

Venue: Room 10

First Author: : M.Morral SPAIN

Co Author(s): :    F. Manero   J. Guell                 

Abstract Details

Purpose:

To compare corneal endothelium safety of iris-claw phakic intraocular lens (PIOL) implantation versus corneal refractive surgery (CRS) or no surgery.

Setting:

Institut de Microcirurgia Ocular (IMO), Barcelona, Spain.

Methods:

This is a retrospective, interventional, non-randomized, paired-eye comparative study, which included patients who underwent PIOL implantation in one eye and corneal refractive surgery (Group 1) or no surgery (Group 2) in the fellow eye between 1998 and 2010. Primary outcome measure was central endothelial cell count (cECC) and percentage of corneal endothelium cell loss. Secondary outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, and complications. Outcome measures were analyzed preoperatively, and 1, 5 and 10 years post-operatively.

Results:

Mean preoperative cECC and at last follow-up were: 2836±379 cells/mm2, and 2654±409 cells/mm2 (mean loss 6.41±8.02%) (Group 1 - PIOLs); and 2880±395 cells/mm2, and 2719±250 cells/mm2 (mean loss 5.59±5.98%) (Group 1 - CRS); 2759±365 cells/mm2, and 2543±419 cells/mm2 (mean loss 7.84±6.83%) (Group 2 - PIOLs); and 2736±307 cells/mm2, and 2552±272 cells/mm2 (mean loss 6.74±3.97%) (Group 2 - no surgery). No significant cell loss was observed after PIOL implantation or CRS. There were no significant differences between PIOL and CRS or PIOL and no surgery (p>0.05).

Conclusions:

Iris-claw PIOL implantation and CRS did not produce any significant corneal endothelial cell loss up to 10 years after surgery.

Financial Interest:

One of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented